Skip to main content

Initiative Status:

Date and Duration: April 2025 – June 2025

Naloxone Access & Integration Sprint

Register Here

Purpose

This educational sprint aims to support healthcare communities in expanding Naloxone access and distribution within perinatal care settings. It will provide an opportunity to explore strategies, implementation approaches, and policy considerations while fighting stigma and breaking down barriers to access. Through shared learning, discussion, and collaboration, this sprint seeks to identify opportunities and practical steps to further normalize and integrate Naloxone in perinatal care. Overall, this intends to strengthen community-wide overdose prevention efforts in Minnesota.

Naloxone Sprint Charter

Session Details

All sessions are held from 12 PM to 1 PM on the following dates:

  • Tuesday, April 22 – Understanding the State of Minnesota with guest speaker Laura Polombi, PharmD, MPH, MAT
  • Tuesday, April 29 – Learning from Other States’ Success
  • Tuesday, May 13 – Hearing MN Community-Driven Solutions
  • Tuesday, May 20 – Identifying Sustainability Metrics
  • Tuesday, June 24 – Final Thoughts and Reflection

Goals & Objectives

Session 1: Kickoff & Education
1. Overview of Naloxone use, availability, and distribution.
2. Addressing stigma and misconceptions in perinatal care.

Session 2: Implementation & Strategy
1. Best practices for integrating Naloxone into maternal healthcare.
2. Policy considerations for sustainable programs.

Session 3: Minnesota Perspectives & Peer Learning
1. Collaborative discussions among providers and healthcare teams.
2. Real-world success stories in perinatal Naloxone distribution.

Session 4: Sustainability & Impact
1. Normalizing Naloxone in standard perinatal care.
2. Strengthening community-wide overdose prevention efforts.

Toolkit

MNPQC’s Quality Improvement Programs were developed with support and guidance from hospital teams and professional faculty throughout the state of Minnesota. The contents do not necessarily represent the official views of, nor an endorsement, by our partners.